Comparing treatments for a serious type of blood clot in the lungs
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This study compares different real-world treatments for a serious but stable type of blood clot in the lungs (called intermediate-high risk pulmonary embolism). It aims to see which treatments work best in everyday patients, including those with other health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a blood clot in the main or large branching arteries of your lungs, confirmed by a CT scan.
- Your symptoms started within the last 14 days.
- You have signs that the clot is putting strain on your heart (enlarged right heart or higher-than-normal troponin/BNP levels), but you are not in shock (blood pressure stable).
- You have not already received clot-busting medicine or a clot-removal procedure for this episode.
- People with other health conditions like cancer or kidney problems can join, as this study looks at real-life patients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares three treatments for an intermediate-high risk pulmonary embolism: a minimally invasive clot removal procedure (embolectomy), a low-dose clot-dissolving medication, or standard blood thinning (heparin). The goal is to see which approach works best to prevent worsening while reducing bleeding risks.
This trial tests a treatment that uses ultrasound to guide a thin tube (catheter) to deliver clot-busting medicine directly into the blood clot in your lung. It may be an option for people whose clot is serious but not yet causing shock, and who have symptoms that started within the last two weeks.
This study looks at how well different treatments work for a blood clot in the lung (pulmonary embolism). It includes people who are getting or have already gotten a clot-dissolving medicine or a catheter procedure to remove the clot.
This trial tests a device called the FlowTriever to remove blood clots from the lungs in people with a pulmonary embolism that is not too severe. The goal is to see if this treatment can help improve heart function and symptoms without major surgery.
This study looks at whether a new way of grouping patients with blood clots in the lungs (pulmonary embolism) can better predict their outcomes. If you join, your health will be tracked for 30 days to see how well this new system works.
This Phase 3 trial tests a catheter-based procedure to remove a lung blood clot (pulmonary embolism) and reduce strain on the heart. It may help people who have specific CT scan signs of right-heart strain.
Hear when a new Pulmonary Embolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.